Visit our Evidence-Based Covid-19 Website and Stay Up to Date with the latest Research.
Volume:9 Issue:10 Number:7 ISSN#:2564-2537
Author Verified
ACE Report #12353
Ace Report Cover Tumour

Reduction in Odds of Pathological Fracture with Denosumab vs Zoledronic Acid for Bone Metastases

How to Cite

OrthoEvidence. Reduction in Odds of Pathological Fracture with Denosumab vs Zoledronic Acid for Bone Metastases. ACE Report. 2020;9(10):7. Available from: https://myorthoevidence.com/AceReport/Report/12353

Study Type:Therapy
OE Level Evidence:1
Journal Level of Evidence:1

Bisphosphonates Versus Denosumab for Prevention of Pathological Fracture in Advanced Cancers With Bone Metastasis: A Meta-analysis of Randomized Controlled Trials.

J Am Acad Orthop Surg Glob Res Rev. 2020 Aug; 4(8): e20.00045.

Contributing Authors: H Al Farii A Frazer L Farahdel F AlFayyadh R Turcotte

Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here


Four studies including 7320 patients with bone metastases from advanced cancer were included in this meta-analysis comparing the likelihood of pathological fracture. Sub-group analyses were performed by tumour origin (endodermal cancer, mesodermal cancer). Pooled results found the likelihood of pathological fracture to be significantly lower in the denosumab group compared to the zoledronic acid g...

To view the full report, start your 30-day free trial today

No credit card required

JOIN Forgot Password?

Not sure if you want to join OrthoEvidence?

Access this report without an Account.

Success, an email containing a link to access this report has been sent to your inbox.

CME Image

Continuing Medical Education Credits

You could be earning 0.5 CME credits for each report you read.

For Reprints and Permissions, click here

Please Login or Join to leave comments.